中文名稱(chēng):CMI-392 | 英文名稱(chēng):CMI-392 |
CAS:205654-37-1 | 品牌: 一研 |
保存條件: Store at -20°C | 產(chǎn)品類(lèi)別: 抑制劑 |
Cas : 205654-37-1 |
產(chǎn)品屬性:
產(chǎn)品名稱(chēng) | 規(guī)格 | CAS號(hào) | 型號(hào) |
CMI-392 | 10mg 5mg 1mg | 205654-37-1 | EY-Y0164083 |
Cas No.205654-37-1
別名 N/A
化學(xué)名 N/A
分子式 C31H37ClN2O8S
分子量 633.15
溶解度 Soluble in DMSO
儲(chǔ)存條件 Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
產(chǎn)品描述:
CMI-392 is a dual 5-lipoxygenese inhibitor and platelet-activating factor (PAF) receptor antagonist with IC50s of 100 and 10 nM, respectively.
Topical treatment of CMI-392 in the acute and chronic TPA models result in a significant decrease of ear weight, inflammatory cell infiltration, and histological examination. The ED50 for PAF-induced mouse hemoconcentration and arachidonic acid-induced mouse ear edema are 2.2 and 1.8 mg/kg, respectively[1].
[1]. Cai X, et al. (+/-)-trans-2-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-(N-methyl-N- hydroxyureidyl)methylphenyl]-5-(3,4, 5-trimethoxyphenyl)tetrahydrofuran (CMI-392), a potent dual 5-lipoxygenase inhibitor and platelet-activating factor receptor antagonist. J Med Chem. 1998 May 21;41(11):1970-9.
成立日期 | 2014-06-05 (11年) | 注冊(cè)資本 | 100 |
員工人數(shù) | 50-100人 | 年?duì)I業(yè)額 | ¥ 100萬(wàn)以?xún)?nèi) |
主營(yíng)行業(yè) | 生化試劑,抗體,細(xì)胞培養(yǎng),分子生物學(xué),免疫安全 | 經(jīng)營(yíng)模式 | 工廠,試劑 |
產(chǎn)品名稱(chēng) | 價(jià)格 | 公司名稱(chēng) | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢(xún)價(jià) |
gl biochem (shanghai)
|
2017-09-20 | ||
¥100 |
西寶生物科技(上海)股份有限公司
|
2017-01-09 | ||
¥19800 |
VIP3年
|
TargetMol中國(guó)(陶術(shù)生物)
|
2024-09-29 |